Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma-Reference-Cited by-同舟云学术

Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma

Published:2006-05 Issue:6 Volume:6 Page:469-474
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Barlogie Bart,Zangari Maurizio,Bolejack Vanessa,Hollmig Klaus,Anaissie Elias,van Rhee Frits,Pineda-Roman Mauricio,Mohiuddin Abid,Crowley John,Tricot Guido

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference23 articles.

1. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma;Jagannath;Br J Haematol,2005

2. Combination therapy with lenalidomide plus dexamethasone (REV/DEX for newly diagnosed myeloma);Rajkumar;Blood,2005

3. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis;Palumbo;Blood,2004

4. PAD combination therapy (PS341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma;Oakervee;Br J Haematol,2005

5. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;N Engl J Med,1996

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs;Clinical Lymphoma Myeloma and Leukemia;2014-04

2. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation—Novel Agents and Immunomodulatory Strategies;Biology of Blood and Marrow Transplantation;2013-12

3. Gene Expression Signature in MGUS and Multiple Myeloma;Genetic and Molecular Epidemiology of Multiple Myeloma;2012-11-23

4. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma;American Journal of Hematology;2011-12-21

5. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma;International Journal of Hematology;2011-10